Novan Inc

Novan — Investor Presentation (November 2016)

25 slides from Novan's investor presentation, Nov 29, 2016

  1. Slide 1: Corporate Presentation November 2016

    Corporate Presentation November 2016 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our operations and financial performance. These forward-looking statements are included throughout this presentation. We have used the words “anticipate,” “assume,” “believe,” “c

  3. Slide 3: Overview

    Technology platform for transforming nitric oxide into new chemical entities and product candidates for a host of skin diseases SB204 – Phase 3 asset with top-line results expected 1Q 2017 Parallel Phase 3 pivotal trials initiated in 1Q 2016; NDA submission targeted for end of 2017 Robust clinical d

  4. Slide 4: Experienced Leadership

    Experienced Leadership Management Team Nathan Stasko, PhD Chief Executive Officer, Director Richard Peterson Chief Financial Officer Brian Johnson, MBA Chief Commercial Officer M. Joyce Rico, MD, MBA Chief Medical Officer Stan Hollenbach, JD VP, Research and Nonclinical Development Kevin Barber, PhD

  5. Slide 5: Our Nitric Oxide Pipeline

    Our Nitric Oxide Pipeline Our focus on these five indications targets disease burden in >150M individuals in the US and >1.5B individuals globally. Product Candidates Indication Target Preclinical / Phase 1 Phase 2 Phase 3 Anticipated Milestones SB204 Acne Vulgaris P. acnes, IL-1, IL-17 Report top l

  6. Slide 6: Nitric Oxide Platform Overview

    Nitric Oxide Platform Overview

  7. Slide 7: Nitric Oxide Mechanisms of Action

    Science – Breakthrough of the Year (1992) Nobel Prize in Medicine (1998) >100,000 peer reviewed manuscripts Broad Spectrum Antimicrobial Anti-bacterial Anti-viral Anti-fungal Immunomodulatory Agent Decreases key biomarkers for inflammation Inhibits T cell proliferation Results in NO-derived regulato

  8. Slide 8: Nitricil Technology

    Nitricil Technology Stable storage Drugable form of nitric oxide with shelf-life stability Therapeutic quantities High loading capacity previously unachievable “Tunability” pH-controlled hydrolysis that releases nitric oxide Engineered macromolecule Targets nitric oxide delivery to the skin Minimize

  9. Slide 9: Formulation Science

    Formulation Science Cosmetic Elegance FDA’s IID For Topical Use Irritation Potential Compatibility with Nitricil In vitro Release Shelf-life Stability Product Candidates (SB204) Nitricil based NCEs Our goal is to balance the need for safe and effective delivery of nitric oxide with physician and pat

  10. Slide 10: Our Nitric Oxide Platform

    Our Nitric Oxide Platform NVN1000 Nitric Oxide Proprietary chemistry that stores large amounts of nitric oxide in solid form Macromolecular NCEs Drug Candidates Indication specific formulations with differentiated nitric oxide release rates Formulation Science Nitricil Technology SB204 SB206 Over 10

  11. Slide 11: Summary of Intellectual Property Portfolio

    Summary of Intellectual Property Portfolio Covered Patent Life Issued Patents (Pending Applications) NitricilTM Technology Composition of Matter Family of Compounds – 8,282,967 NVN1000 Composition – 8,956,658 NVN4000 Composition – 8,962,029 Method of Manufacture to 2026 to 2032 US, Japan, Australia

  12. Slide 12: SB204 Potential First-in-Class Topical for the Treatment of Acne

    SB204 Potential First-in-Class Topical for the Treatment of Acne

  13. Slide 13: Nitric Oxide and Acne

    Nitric Oxide and Acne Hanna-Leena Kelhälä et al. PLoS One. 2014;9(8): e105238. Niedbala W et al. Proc Natl Acad Sci USA. 2011;108(22):9220-9225. Niedbala W et al. J Immunol. 2013;191(1):164-170. Qin M et al. J Invest Dermatol. 2015;135(11):2723-2731. P. acnes Excess sebum Inflammation Hyper-keratini

  14. Slide 14: SB204

    SB204 SB204 Activating Hydrogel NVN1000 Alcohol Gel SB204 is a once-daily, fast-acting, cosmetically elegant topical gel currently in Phase 3 clinical development for the treatment of acne vulgaris Potential first-in-class topical treatment that has shown evidence of efficacy against both inflammato

  15. Slide 15: Phase 3 Pivotal Trial Design

    1,300 patients per trial x 2 pivotals = 2,600 patients total 1:1 randomization, SB204 4% Once Daily vs Vehicle Once Daily 12 weeks of treatment Inclusion Criteria Ages 9 and up Minimum 20 and no more than 40 inflammatory lesions on the face Minimum 25 and no more than 70 non-inflammatory lesions on

  16. Slide 16: SB206 Product Candidate for the Treatment of Viral Skin Infections

    SB206 Product Candidate for the Treatment of Viral Skin Infections

  17. Slide 17: Human Papilloma Virus (HPV) Associated Warts

    Human Papilloma Virus (HPV) Associated Warts Prevalence HPV affects nearly 80 million Americans 14 million people become infected each year Over 100 subtypes, low and high risk strains Prevalence of warts in the US: Genital warts exceeds 500,000 people Common warts exceeds 3,000,000 people Infection

  18. Slide 18: Phase 2 Clinical Study of SB206

    Phase 2 Clinical Study of SB206 12 week treatment duration SB206 4% gel 2x/day SB206 4% gel 1x/day Vehicle gel 1x/day SB206 8% gel 1x/day Primary endpoint Secondary endpoints include: Proportion of patients at week 12 who are completely clear of warts present at baseline Proportion of patients at we

  19. Slide 19: Phase 2 Patient Demographics and Disposition

    Phase 2 Patient Demographics and Disposition Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 24) SB204 8% gel QD (n = 14) SB204 12% gel QD (n = 30) Gender, n (%) Male 19 (70.4%) 6 (50.0%) 16 (66.7%) 12 (85.7%) 23 (76.7%) Female 8 (29.6%) 6 (50.0%) 8 (33.3%) 2 (14.3%) 7 (23

  20. Slide 20: Treatment-Emergent and Application-Site Adverse Events

    Phase 2 Treatment-Emergent and Application-Site Adverse Events Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 23) SB204 8% gel QD (n = 14) SB204 12% gel QD (n = 30) General Disorders and Administration-Site Conditions 1 (4.2%) 6 (50.0%) 6 (26.1%) 1 (7.1%) 5 (16.7%) Burn 0

  21. Slide 21: Primary Endpoint Complete Clearance of Baseline Warts

    Phase 2 Primary Endpoint Complete Clearance of Baseline Warts (ITT & PP analyses) p=0.0099 p=0.0200 Solid (ITT) Lined (PP)

  22. Slide 22: SB206 Research Collaborations

    SB206 Research Collaborations In vitro and in vivo data generated with collaborators who are at the cutting edge of HPV disease pathology research. Dr. Neil Christensen, Professor of Pathology, and Microbiology and Immunology; Medical Director, Jake Gittlen Cancer Research Foundation Research Intere

  23. Slide 23: Nitric Oxide Inhibition of Viral Replication

    Nitric Oxide Inhibition of Viral Replication HPV-18 Infected Human Epidermis Grown in Culture BrdU Stain (mitotic index for rapidly dividing nuclei) Untreated Control 1.5 mg/mL NVN1000 qPCR analysis of HPV-18 viral copy number Large number of BrdU stained cells indicative of pervasive viral infectio

  24. Slide 24: Dose Ranging of SB206 Compared to Topical Imiquimod

    Dose Ranging of SB206 Compared to Topical Imiquimod Wild Type Virus E8 Mutant Virus The E8 mutant virus produces slower-growing and more clinically relevant papillomas than the Wild Type virus Dose responsive, pharmacologic effect of SB206 against papillomavirus in a Cottontail Rabbit model

  25. Slide 25: Upcoming Milestones

    Upcoming Milestones SB204 (Acne vulgaris) SB206 (Anti-viral) SB208 (Anti-fungal) Report TLRs from Phase 3 pivotal trials Report TLRs from Phase 2 clinical trial Commence Phase 2 anti-fungal program Targeted NDA Submission Report TLRs from 40 wk LTS Study Complete enrollment in both Phase 3 pivotal t

Novan — Investor Presentation (November 2016) on 6ix